Maze Therapeutics’ Claims For Unapproved Kidney Disease Drug Face Regulatory Scrutiny

 
• By Sue Sutter
  
Winner
Vertex objected to claims that Maze's kidney disease drug offered better potency and efficacy. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Marketing & Advertising

More from United States